The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...und up to 3 times more often in people who had previous exposure to antiretroviral drugs. In addition, nearly half of infants newly diagnosed with HIV has HIVDR to NNRTI before initiating treatment.The high levels of observed NNRTI pretreatment HIVDR among emphasize the need to fast-track the transition to WHO-recommended dolutegravir-based ART.
more
Interim guidance, 6 October 2021
Direct detection of SARS-CoV-2 viral proteins (antigens) in nasal swabs and other respiratory secretions using lateral flow immunoassays (also known as rapid diagnostic tests, RDTs) offers a faster and less expensive method to test for SARS-CoV-2 than the reference ...method, nucleic acid amplification tests (NAATs). This interim guidance offers recommendations on the priority uses of antigen-detecting rapid diagnostic tests (Ag-RDTs) in specific populations and settings, including (i) for primary case detection in symptomatic individuals suspected to be infected and asymptomatic individuals at high risk of COVID-19, (ii) for contact tracing, (iii) during outbreak investigations and (iv) to monitor trends of disease incidence in communities. Ag-RDTs meeting minimum performance requirements can be used outside of clinical and laboratory settings, including in communities, by trained operators in accordance with instructions. The guidance additionally provides recommendations on implementation, product selection and storage.
more
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
This is a guidance document for countries and implementing partners on the technical requirements for developing digital information systems for issuing standards-based interoperable digital certificates for COVID-19 vaccination status, and considerations for implementation of such systems, for the ...purposes of continuity of care, and proof of vaccination.
more
Drawing light from the pandemic: A new strategy for health and sustainable development (2021)
Available in English, French, German and Russian
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
Orientations provisoires 19 juillet 2021
Establecida en 1902 como el organismo independiente especializado en salud del sistema interamericano, la Organización Panamericana de la Salud (OPS) ha desarrollado competencias y experiencia ampliamente reconocidas al brindar cooperación técnica a sus Estados Miembros para combatir las enfermed...ades transmisibles y no transmisibles y sus causas, fortalecer los sistemas de salud y responder a situaciones de emergencia y desastres en toda la Región de las Américas. Asimismo, en su calidad de oficina regional de la Organización Mundial de la Salud, la OPS participa activamente en los equipos de las Naciones Unidas en los países, colaborando con otros organismos, fondos y programas del sistema de las Naciones Unidas para contribuir al logro de los Objetivos de Desarrollo Sostenible (ODS) a nivel de país.
more
La presente publicación describe la evidencia científica disponible sobre la efectividad del uso de mascarillas o respiradores en la prevención y control de infecciones respiratorias virales incluido COVID-19 a nivel comunitario y hospitalario. Se identificaron 778 estudios publicados hasta abril... de 2020 como parte de la búsqueda sistemática de evidencias (320 población general y 452 personal de salud). Siete estudios fueron seleccionados para responder a las preguntas de investigación de los cuales cinco fueron ensayos clínicos respecto al subgrupo de población general y una revisión sistemática y un ensayo clínico respecto al subgrupo de personal de salud.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
more
El presente documento compila cronológicamente la normatividad legal-administrativa de salud, del diario oficial El Peruano y normas internas de la institución, de acuerdo al tema de COVID-19, correspondiente al segundo semestre 2020.
El presente protocolo se aplica en las Instituciones Prestadoras de Servicios de Salud del Ministerio de Salud, a través de las Direcciones de Redes Integradas de Servicios de Salud y de los gobiernos regionales, a través de las Direcciones Regionales de Salud o Gerencias Regionales de Salud , EsS...alud, Sanidad de las Fuerzas Armadas y Policiales y las entidades privadas.
En el documento encontrarás consideraciones generales y específicas, así como información sobre el flujo de atención (admisión, triaje, punto de vacunación, monitoreo y observación), entre otros.
more
September – December 2021
The funds will be used by WHO to ensure:
continued coordination with other agencies and health actors in the response to the crisis situation
continuity of health services for the population of Afghanistan
provision of life-saving medical supplies
con...tinued response to COVID-19
timely response to potential outbreaks
response to urgent trauma needs
more
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch...ildren. If children with mild or no symptoms transmit the disease, they may act as drivers of transmission within their communities. Understanding symptoms, infectivity and patterns of SARS-CoV-2 transmission in children and adolescents is essential for developing, adapting and improving control measures for COVID-19 across all ages. This is a summary of the current knowledge around SARS-CoV-2 infection acquisition and transmission and COVID-19 disease symptoms in children and adolescents. It aims to inform decisions, based on local contexts, on how to best keep schools, kindergarten and day-care facilities open and what advice to apply to intergenerational mixing.
more
Les infections au SRAS-CoV-2 chez les enfants et les adolescents provoquent une maladie moins grave et moins de décès que chez les adultes. Bien qu'une évolution moins grave de l'infection soit un résultat positif, on s'inquiète du fait que des symptômes légers aient pu conduire à moins de t...ests, ce qui a entraîné un nombre moins important de cas identifiés de COVID-19 chez les enfants. Si les enfants présentant des symptômes légers ou inexistants transmettent la maladie, ils peuvent agir comme des vecteurs de transmission au sein de leur communauté. Il est essentiel de comprendre les symptômes, l'infectivité et les modes de transmission du SRAS-CoV-2 chez les enfants et les adolescents pour développer, adapter et améliorer les mesures de contrôle du COVID-19 à tous les âges. Ce document est un résumé des connaissances actuelles concernant l'acquisition et la transmission de l'infection par le SRAS-CoV-2 et les symptômes de la maladie COVID-19 chez les enfants et les adolescents. Il vise à éclairer les décisions, en fonction des contextes locaux, sur la meilleure façon de maintenir ouvertes les écoles, les jardins d'enfants et les crèches et sur les conseils à appliquer en matière de mixité intergénérationnelle.
more
La détection directe des protéines virales du SRAS-CoV-2 (antigènes) dans les écouvillons nasaux et autres sécrétions respiratoires à l'aide de tests immunologiques à flux latéral (également appelés tests de diagnostic rapide, TDR) offre une méthode plus rapide et moins coûteuse pour te...ster le SRAS-CoV-2 que la méthode de référence, les tests d'amplification des acides nucléiques (TAAN). Ces lignes directrices provisoires offrent des recommandations sur les utilisations prioritaires des tests de diagnostic rapide à détection d'antigène (TDR-Ag) dans des populations et des contextes spécifiques, notamment (i) pour la détection primaire des cas chez les personnes symptomatiques suspectées d'être infectées et les personnes asymptomatiques à haut risque de COVID-19, (ii) pour la recherche des contacts, (iii) pendant les enquêtes sur les épidémies et (iv) pour surveiller les tendances de l'incidence de la maladie dans les communautés. Les TDR-AG répondant aux exigences minimales de performance peuvent être utilisés en dehors des milieux cliniques et des laboratoires, y compris dans les communautés, par des opérateurs formés conformément aux instructions. Le guide fournit en outre des recommandations sur la mise en œuvre, la sélection des produits et le stockage
more
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...al dose of all WHO approved vaccines “since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease.”
People aged 60 and older who received the Sinovac and Sinopharm vaccines should get a third dose too, the experts added, though use of other vaccines may also be considered depending on supply and access.
“When implementing this recommendation, countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting in the oldest age groups”, they said.
SAGE has also reviewed a vaccine developed by Indian company Bharat Biotech and will issue a policy recommendation after WHO greenlights it for emergency use.
more
Временное руководство, Первый выпуск 8 января 2021 г., Обновлено 15 июня 2021 г., Обновлено 19 ноября 2021 г.